Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.
Also called NCT03476616
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 198 participants
- Registry
-
NCT03476616
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Greece
- Registry status
- Completed
Technical summary
Registry record NCT03476616. Randomized; no masking; primary purpose treatment. Start 2018-09-01 (actual); primary completion 2025-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients
- Acronym
- HEBRO
- Condition
- Hypertension
- Condition
- Obesity
- Intervention (Drug)
- Eplerenone (-based therapy) arm
- Intervention (Drug)
- Valsartan (-based therapy) arm
- Lead sponsor
- Hippocration General Hospital
Record details
- Record id
cardio:ct-nct03476616- Content hash
8913e3386451c6c8313dafdbfe6a4773a3032751dc574122df5b6aba1e89bb08